(Q34568303)
Statements
1 reference
The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee (English)
1 reference
Pol F Boudes
1 reference
1 October 2006
1 reference
1 reference
27
1 reference
5
1 reference
432-440
1 reference
Identifiers
1 reference
1 reference